Ribonucleotide reductase inhibitor
From Wikipedia, the free encyclopedia
Drugs used in cancer treatment
Ribonucleotide reductase inhibitors are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides (building blocks of DNA).
Examples include:
- motexafin gadolinium.[1]
- hydroxyurea[2]
- fludarabine, cladribine, gemcitabine, tezacitabine, and triapine[3]
- gallium maltolate, gallium nitrate[4]
- Tezacitabine, Tezacitabine[5] A chemotherapy candidate nucleotide analogue that failed in clinical trials due to on-target toxicity (febrile neutropenia).[6]
References
- ↑ Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (January 2009). "Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)". Biochem. Biophys. Res. Commun. 379 (3): 775–9. Bibcode:2009BBRC..379..775Z. doi:10.1016/j.bbrc.2008.12.128. PMID 19121624.
- ↑ Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS (September 2002). "Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea". Antivir. Chem. Chemother. 13 (5): 305–14. doi:10.1177/095632020201300506. PMID 12630679.
- ↑ Tsimberidou AM, Alvarado Y, Giles FJ (August 2002). "Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies". Expert Rev Anticancer Ther. 2 (4): 437–48. doi:10.1586/14737140.2.4.437. PMID 12647987. S2CID 30047759.
- ↑ Bernstein LR (1998). "Mechanisms of therapeutic activity for gallium" (PDF). Pharmacol. Rev. 50 (4): 665–682. doi:10.1016/S0031-6997(24)01383-8. PMID 9860806. Archived from the original (PDF) on 2007-02-26. Retrieved 2009-06-01.
- ↑ Bitonti, A. J.; Dumont, J. A.; Bush, T. L.; Cashman, E. A.; Cross-Doersen, D. E.; Wright, P. S.; Matthews, D. P.; McCarthy, J. R.; Kaplan, D. A. (15 March 1994). "Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase". Cancer Research. 54 (6): 1485–1490. PMID 8137252.
- ↑ "Tezacitabine monohydrate".
External links
- Ribonucleotide reductase inhibitor entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
| Class | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Substrate |
| ||||||||||
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |